Clinical Trials Browser

Phase 1/2 × tucatinib × 90 days × Clear all

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Phase 1/2 Active not recruiting

HER2-positive Metastatic Breast Cancer

NCT06686394 2026-02-13

MK-1022-009

Phase 1/2 Recruiting

Breast Neoplasms